Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5781)
  3. Review (421)
  4. Editorial (196)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (62)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13278)
  2. Center for Hematologic Malignancies (10612)
  3. GSK Faculty (4482)
  4. Adult Leukemia (3673)
  5. Bone Marrow Transplant (2848)
  6. Lymphoma (2705)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (669)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (340)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3529)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (330)
  5. Haematologica (292)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3806)
  2. Elsevier Inc. (1530)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1009)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13379)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP ) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study
    Meeting Abstract

    Dietrich, S.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J.; Herbaux, C.; Burke, J. M.; Matasar, M.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Efficacy of niraparib by timing of surgery and residual disease: A post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
    Meeting Abstract

    O'Cearbhaill, R.; Grabowski, J.; Pérez-Fidalgo, J. A.; Monk, B. J.; Tusquets, I.; Mccormick, C.; Pradera, J. F.; Moore, R. G.; Vulsteke, C.; Shahin, M.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma, myxoid/round cell liposarcoma and nonsmall cell lung cancer [Substudy 1 (GSK3901961) and Substudy 2 (GSK3845097)]
    Meeting Abstract

    Ullrich, R.; Wermke, M.; Yachnin, J.; Mielke, S.; Patel, R.; Yushak, M. L.; Schoenfeld, A. J.; Desai, J.; Altan, M.; D'Angelo, S. P.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Identifying patterns of failure after initial therapy in primary CNS lymphoma in a large patient cohort
    Meeting Abstract

    Tringale, K.; Yahalom, J.; Scordo, M.; Vachha, B.; Schaff, L.; Grommes, C.; Imber, B.
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy data on two patients with relapsed/refractory CNS lymphoma treated with emavusertib (CA-4948) and ibrutinib combination: A subset analysis of TakeAim Lymphoma trial
    Meeting Abstract

    Iqbal, M.; Tun, H.; Joffe, E.; Grommes, C.; Nowakowski, G.; Lunning, M.; Ramchandren, R.; Li, C. C.; Zhao, W.; Martinez, E.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600-or NRAS-mutant melanoma
    Meeting Abstract

    Lebbe, C.; Long, G. V.; Robert, C.; Hamid, O.; Atkinson, V. G.; Shoushtari, A. N.; Daud, A.; Bechter, O. E.; Schadendorf, D.; Sullivan, R. J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)
    Meeting Abstract

    Lang, J.; Tagawa, S. T.; Slovin, S.; Emamekhoo, H.; Rathkopf, D.; Abida, W.; Autio, K.; Xiao, H.; Molina, A. M.; Eickhoff, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)
    Meeting Abstract

    Cytryn, S.; Joshi, S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; Rao, D.; Goldberg, Z.; Sugarman, R.; Antoine, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Characterizing the clinico-genomic landscape and outcomes of KRAS G12C mutated pancreas cancer
    Meeting Abstract

    Keane, F.; Park, W.; Varghese, A.; Balogun, F.; Yu, K.; El Dika, I.; Khalil, D.; Kelsen, D. P.; Reidy-Lagunes, D.; Ku, G. Y.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Updated analysis of DESTINY-Gastric02: A phase II singlearm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/ metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen
    Meeting Abstract

    Ku, G. Y.; Di Bartolomeo, M.; Smyth, E.; Chau, I.; Park, H.; Siena, S.; Lonardi, S.; Wainberg, Z. A.; Ajani, J. A.; Chao, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save